Tag: markets

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

Sydney, Australia, June 07, 2026 (GLOBE NEWSWIRE) -- With annual inflation at 4.6% in the year to March 2026 and roughly 4.4 million Australians now aged 65 and over, retirees face a sharpening challenge: turning a lifetime of savings into income that keeps pace with the rising cost of groceries, fuel and everyday essentials. The pressure is compounded by longevity, with many Australians spending two or even three decades in retirement, and by a shift in mindset that retirement itself demands. In the accumulation years, investors can ride out market volatility and recover losses over time; in the drawdown phase, with shorter horizons and less capacity to recoup losses, the priority moves to predictable income and preserving purchasing power. To learn more visit https://termplus.com.au/insights-news/news/turning-savings-into-reliable-monthly-income-in-retirement/

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),² and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6